Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 74,787 | 62,898 | 54,116 | 41,374 | 45,059 |
| Cost of Goods | 2,553 | 1,626 | 2,061 | 1,504 | 4,564 |
| Gross Profit | 72,234 | 61,272 | 52,055 | 39,870 | 40,495 |
| Operating Expenses | 133,524 | 118,047 | 119,820 | 179,611 | 135,292 |
| Operating Income | -60,737 | -56,149 | -67,704 | -139,237 | -94,233 |
| Interest Expense | 2,817 | 2,777 | 2,788 | 2,800 | 2,820 |
| Other Income | 3,214 | 4,090 | 925 | 6,270 | 8,525 |
| Pre-tax Income | -60,340 | -54,836 | -69,567 | -135,767 | -88,528 |
| Income Tax | -72 | -84 | 85 | 191 | 68 |
| Net Income Continuous | -60,268 | -54,752 | -69,652 | -135,958 | -88,596 |
| Net Income Discontinuous | 4 | -59 | -757 | -103 | -1,577 |
| Net Income | $-60,264 | $-54,811 | $-70,409 | $-136,061 | $-90,173 |
| EPS Basic Total Ops | -0.71 | -0.70 | -0.91 | -1.76 | -1.07 |
| EPS Basic Continuous Ops | -0.70 | -0.70 | -0.90 | -1.76 | -1.14 |
| EPS Basic Discontinuous Ops | 0.00 | 0.00 | -0.01 | 0.00 | 0.07 |
| EPS Diluted Total Ops | -0.71 | -0.70 | -0.91 | -1.76 | -1.07 |
| EPS Diluted Continuous Ops | -0.70 | -0.70 | -0.90 | -1.76 | -1.14 |
| EPS Diluted Discontinuous Ops | 0.00 | 0.00 | -0.01 | 0.00 | 0.07 |
| EPS Diluted Before Non-Recurring Items | -0.73 | -0.70 | -0.90 | N/A | N/A |
| EBITDA(a) | $-51,456 | $-44,910 | $-57,359 | $-129,357 | $-90,483 |